Group | Number of patients | MPAP | SD | Systolic Regression | R2 | Diastolic Regression | R2 | ||
---|---|---|---|---|---|---|---|---|---|
Normal | 83 | 19 | 3.6 | 0.50 SPAP + 3.36 | 0.777 | 1.11DPAP + 4.00 | 0.976 | ||
Group 1 | 135 | 50 | 12,8 | 0.58 SPAP + 3.52 | 0.995 | 1.16DPAP + 9.68 | 0.995 | ||
IPAH | 68 | 51 | 11,2 | 0.60 SPAP + 2.35 | 0.838 | 1.10DPAP + 11.6 | 0.878 | ||
Medication induced PAH | 10 | 51 | 13,9 | 0.61 SPAP + 0.02 | 0.991 | 1.44DPAP+ 0.43 | 0.989 | ||
Cirrhosis | 15 | 52 | 12,5 | 0.60 SPAP −0.06 | 0.990 | 1.45DPAP + 1.07 | 0.986 | ||
Congenital | 13 | 57 | 16,8 | 0.61 SPAP −1.03 | 0.986 | 1.44DPAP + 1.50 | 0.976 | ||
Systemic sclerosis | 22 | 44 | 12,5 | 0.61 SPAP + 1.65 | 0.966 | 1.10DPAP + 4.07 | 0.939 | ||
HIV | 2 | 62 | a | ||||||
Hereditary | 1 | 49 | a | ||||||
schistosomiasis | 1 | 50 | a | ||||||
veno-occlusive disease | 3 | 47 | a | ||||||
Group 2 | 109 | 38 | 10,8 | 0.59 SPAP + 3.57 | 0.877 | 1.25 DPAP + 3.25 | 0.867 | ||
Group 3 | 26 | 39 | 9,4 | 0.54 SPAP+ 5.62 | 0.908 | 1.31 DPAP + 1.75 | 0.877 | ||
Group 4 | 63 | 44 | 10.4 | 0.53 SPAP + 3.93 | 0.789 | 1.12 DPAP + 11.50 | 0.987 | ||
Group 5 | 12 | 44 | 11,04 | 0.53 SPAP + 6.38 | 0.976 | 1.45 DPAP-0.20 | 0.856 | ||
Unclassifed | 1 | 43 | a | a | a | a | a |